

PRESS RELEASE

FyoniBio and adivo GmbH sign a Service Agreement covering the generation of a production cell line for their canine therapeutic mAb candidate



Berlin, Germany and Munich, Germany, January 10, 2023:

FyoniBio, a CDO expert specialized in tailored cell line development and adivo a leader in discovering species-specific therapeutic antibodies for pets are pleased to announce the signing of a cell line development agreement. adivo is transitioning its most advanced proprietary therapeutic canine mAb candidate, which has been granted the limited market authorization status by the European Medicines Agency (EMA) into first-in-animal studies.

For the project, FyoniBio will use its versatile CHOnamite® cell line development platform, that integrates a high-performance Transposase technology and comprises various host cell lines to select the most suitable cell line to produce adivo's canine mAb format at the highest quality and yield.

"We are delighted with this very collaborative project partnership with adivo, which demonstrates an excellent fit between the project teams on both sides and that our CHOnamite® platform is ideally suited to generate highly productive cell lines for canine antibodies as well," outlined Dr. Lars Stöckl, Managing Director at FyoniBio.

“We are excited to work with FyoniBio, whom we have chosen for their extensive experience in biopharma development and their ability to provide tailor-made services for companies of various sizes and at different development stages. Advancing a product candidate from lab-scale manufacturing to providing trial-grade material is a pressure test for any therapeutic project and a significant value inflection point,” commented Dr. Philipp Baer, Chief Scientific Officer of adivo.

FyoniBio Facts

FyoniBio’s ISO-9001 certified service portfolio covers the development chain from cell line development, process development and in-depth analytical characterization, including bioassays and clinical sample monitoring under GCLP. FyoniBio’s expertise builds on the long-standing experience of our scientists who have developed various cell lines and processes which entered late-stage clinical trials. Our customized approaches enable rapid, high-titer cell line development in various mammalian host cell lines specialized in meeting individual product requirements. Besides our CHOnamite® platform, we provide the human GEX® platform, which is particularly suited for recombinant proteins with complex glycan structures. Furthermore FyoniBio is highly skilled in mass spectrometry based in-depth analytical characterization of biopharmaceuticals and offers the whole package of clinical sample analysis from assay establishment, validation and measurement of clinical samples under GCLP.

All services are established according to our internal quality management system to assure compliance with international ISO standard and meeting international GMP standards.

adivo Facts

adivo is forging a new era for companion animal health. Our proprietary phage display antibody libraries deliver species-specific drugs for a growing market need. We apply our extensive drug discovery and protein engineering know-how to address cancer, chronic inflammatory diseases and other serious conditions in pets. Together with our partners, we create the best possible therapeutics for our beloved furry friends. For further information, please visit: www.adivo.vet/

FyonBio Contact:

Dr. Ulrike Scheffler; Senior Director Business Development

E-mail: contact@fyonibio.com

Phone: +49 (0) 17619489825

www.fyonibio.com

adivo Contact:

Dr. Kathrin Ladetzki-Baehs, CEO

Phone +49 89 58 8088 471

E-mail: info@adivo.vet